Lung cancer screening: from imaging to biomarker

Area of Science:

• Oncology
• Radiology
• Biomarker Research

Background:

• Lung cancer remains a leading cause of cancer death globally.
• High mortality is linked to late diagnosis, metastasis, and ineffective treatments for advanced disease.
• Early detection through screening is vital for curative surgical intervention.

Purpose of the Study:

• To review the history and effectiveness of lung cancer screening methods.
• To discuss advancements in serum biomarker detection for lung cancer.
• To highlight the importance of early detection for improving patient outcomes.

Main Methods:

• Review of historical lung cancer screening trials including chest X-ray (CXR), sputum cytology, and computed tomography (CT).
• Analysis of the National Lung Screening Trial (NLST) results using low-dose spiral CT (LDCT).
• Examination of various serum biomarkers such as circulating DNA/RNA, exosomal microRNA, and tumor cells.

Main Results:

• Most historical screening methods (CXR, sputum cytology) have not improved survival.
• The National Lung Screening Trial (NLST) demonstrated a 20% mortality reduction with LDCT screening in high-risk populations.
• Emerging serum biomarkers show promising results for lung cancer detection.

Conclusions:

• Low-dose CT screening has shown potential in reducing lung cancer mortality.
• Serum biomarker research offers a promising avenue for novel lung cancer detection methods.
• Continued research and development in screening technologies are essential for early lung cancer diagnosis and improved survival.